SMAD4 mutation	Colorectal Cancer	SMAD4 mutation	Colorectal Cancer	cetuximab + panitumumab Sensitive: C3 – Early Trials cetuximab + panitumumab Sensitive : C3	cetuximab + panitumumab Sensitive: C3 – Early Trials cetuximab + panitumumab Sensitive : C3
SMAD4 mutation	Colorectal Cancer	SMAD4 mutation	Colorectal Cancer	panitumumab Sensitive: C3 – Early Trials panitumumab Sensitive : C3	panitumumab Sensitive: C3 – Early Trials panitumumab Sensitive : C3
SMAD4 mutation	Colorectal Cancer	SMAD4 mutation	Colorectal Cancer	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3
SMAD4 mutation	Biliary Tract Cancer	SMAD4 mutation	Biliary Tract Cancer	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3
SMAD4 mutation	Pancreatic Cancer	SMAD4 mutation	Pancreatic Cancer	Immunotherapy Sensitive: C4 – Case Studies Immunotherapy Sensitive : C4	Immunotherapy Sensitive: C4 – Case Studies Immunotherapy Sensitive : C4
SMAD4 mutation	Squamous Cell Carcinoma of Head and Neck	SMAD4 mutation	Squamous Cell Carcinoma of Head and Neck	olaparib Sensitive: D – Preclinical olaparib Sensitive : D	olaparib Sensitive: D – Preclinical olaparib Sensitive : D
SMAD4 mutation	Colon Cancer	SMAD4 mutation	Colon Cancer	oxaliplatin Sensitive: D – Preclinical oxaliplatin Sensitive : D	oxaliplatin Sensitive: D – Preclinical oxaliplatin Sensitive : D

SMAD4 mutation

Associations